Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04037241
Recruitment Status : Not yet recruiting
First Posted : July 30, 2019
Last Update Posted : July 15, 2020
Sponsor:
Information provided by (Responsible Party):
Sorrento Therapeutics, Inc.

Brief Summary:
This study is a randomized open-label phase 2b study of the efficacy and safety of regional infusion therapy with Anti-CEA CAR-T cells using the hepatic immunotherapy for metastases (HITM) method and the Trisalus pressure enabling drug delivery (PEDD) device alternating with systemic chemotherapy versus chemotherapy alone in patients with CEA-expressing pancreatic adenocarcinoma with liver metastases.

Condition or disease Intervention/treatment Phase
Malignant Tumor of Pancreas Metastatic to Liver Biological: Anti-CEA CAR-T cells Drug: gemcitabine/nab paclitaxel Drug: NLIR+FU/FA Drug: Capecitabine Phase 2 Phase 3

Detailed Description:

The study consists of 5 periods: Screening/Leukapheresis Period, Bridging Therapy Period, Randomization Period, Treatment Period, and Observation Period (which will be the long-term follow-up period to monitor for overall survival and long-term safety).

Patients in this trial with CEA-expressing pancreatic adenocarcinoma with liver metastases must have developed disease progression after first-line treatment with FOLFIRINOX (irinotecan, 5-fluorouracil, leucovorin, and oxaliplatin) or gemcitabine-based chemotherapy. Patients will be randomized to either the "anti-CEA CAR-T Cells + systemic chemotherapy treatment arms", or the "chemotherapy alone treatment arms."

If the patients achieve at least stable disease during the Bridging Therapy Period, they will be in the Second-Line Group of Treatment Arms. Patients who develop disease progression during the Bridging Period will be in the Third-Line Group of Treatment Arms.

Patients in the Second-Line or Third-Line treatment arms who are randomized to the treatment arms of "Anti-CEA CAR-T cells plus systemic chemotherapy" will receive hepatic infusions of Anti-CEA CAR-T cells in Cycles 1 and 3 (ie, each 42-day cycle is 3 weekly doses of Anti-CEA CAR-T cells administered as hepatic arterial infusions using a PEDD device with low dose systemic IL-2 support), alternating with the systemic chemotherapy regimen they received during the Bridging Therapy Period in Cycle 2 and Cycles >= 4. Systemic chemotherapy will be administered in 28-day cycles until the development of disease progression.

Patients in the Second-Line or Third-Line treatment arms who are randomized to the treatment arms "chemotherapy alone" arms will continue to receive the same systemic chemotherapy that they received during the Bridging Therapy Period. Systemic chemotherapy will be administered in 28-day or 21-day cycles (depending on the type of systemic chemotherapy regimen the patient will receive) until the development of disease progression.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 167 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Open-Label Phase 2b Study of Hepatic Infusions of Anti-CEA CAR-T Cells Alternating With Systemic Chemotherapy Versus Chemotherapy Alone In Patients With Liver Metastases Due To CEA-Expressing Pancreatic Adenocarcinoma
Estimated Study Start Date : November 1, 2021
Estimated Primary Completion Date : January 1, 2022
Estimated Study Completion Date : January 1, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 2nd Line: Anti-CEA CAR-T Cells + gemcitabine/nab paclitaxel
Patients in the "anti-CEA CAR-T Cells plus gemcitabine/nab paclitaxel arm" will have achieved at least stable disease during the Bridging Therapy Period with gemcitabine/nab paclitaxel, and will receive the CAR-T cells in Cycles 1 and 3 and the gemcitabine/nab paclitaxel regimen they received during the Bridging Therapy Period in Cycle 2 and Cycles ≥ 4 of the Treatment Period. Treatment will continue until the development of disease progression.
Biological: Anti-CEA CAR-T cells
Doses will be delivered by hepatic arterial infusions using a pressure enabled drug delivery (PEDD) device
Other Names:
  • SureFire Precision Infusion System
  • K171355
  • TriSalus PEDD

Drug: gemcitabine/nab paclitaxel
systemic chemotherapy regimen
Other Names:
  • Gemzar
  • Abraxane

Experimental: 2nd Line: Anti-CEA CAR-T Cells Plus NLIR+FU/FA
Patients in the "anti-CEA CAR-T Cells plus and nanolipsomal irinotecan (NLIR) + Fluorouracil/folinic acid (FU/FA)" will have achieved at least stable disease during the Bridging Therapy Period with NLIR + FU/FA, and will receive the CAR-T cells in Cycles 1 and 3 and the NLIR/FU/FA regimen they received during the Bridging Therapy Period in Cycle 2 and Cycles ≥ 4 of the Treatment Period. Treatment will continue until the development of disease progression.
Biological: Anti-CEA CAR-T cells
Doses will be delivered by hepatic arterial infusions using a pressure enabled drug delivery (PEDD) device
Other Names:
  • SureFire Precision Infusion System
  • K171355
  • TriSalus PEDD

Drug: NLIR+FU/FA
systemic chemotherapy regimen
Other Names:
  • Onivyde
  • Adrucil
  • Leucovorin

Active Comparator: 2nd Line: Gemcitabine /nab paclitaxel Alone
Patients in the chemotherapy alone treatment arm who achieved at least stable disease during the Bridging Therapy Period while receiving gemcitabine plus nab paclitaxel will continue treatment with the chemotherapy regimen they received during the Treatment Period. This regimen will be administered in 28-day cycles until the development of disease progression.
Drug: gemcitabine/nab paclitaxel
systemic chemotherapy regimen
Other Names:
  • Gemzar
  • Abraxane

Active Comparator: 2nd Line: NLIR + FU/FA Alone
Patients in the chemotherapy alone treatment arm who achieved at least stable disease during the Bridging Therapy Period while receiving nanoliposomal irinotecan (NLIR) + Fluorouracil/folinic acid (FU/FA) will continue treatment with the chemotherapy regimen they received during the Treatment Period. This regimen will be administered in 28-day cycles until the development of disease progression.
Drug: NLIR+FU/FA
systemic chemotherapy regimen
Other Names:
  • Onivyde
  • Adrucil
  • Leucovorin

Experimental: 3rd Line: Anti-CEA CAR-T Cells Plus NLIR+FU/FA
Patients randomized to the anti-CEA CAR-T Cells plus chemotherapy treatment arm who developed disease progression during the Bridging Therapy Period will receive the CAR-T cells in Cycles 1 and 3. Nanoliposomal irinotecan plus fluorouracil/leucovorin chemotherapy will be administered in Cycle 2 and Cycles ≥ 4 of the Treatment Period to patients who progressed on nab paclitaxel plus gemcitabine during the Bridging Therapy Period. Treatment will continue until the development of disease progression.
Biological: Anti-CEA CAR-T cells
Doses will be delivered by hepatic arterial infusions using a pressure enabled drug delivery (PEDD) device
Other Names:
  • SureFire Precision Infusion System
  • K171355
  • TriSalus PEDD

Drug: NLIR+FU/FA
systemic chemotherapy regimen
Other Names:
  • Onivyde
  • Adrucil
  • Leucovorin

Experimental: 3rd Line: Anti-CEA CAR-T Cells Plus Capecitabine
Patients randomized to the anti-CEA CAR-T Cells plus chemotherapy treatment arm who developed disease progression during the Bridging Therapy Period will receive the CAR-T cells in Cycles 1 and 3. Capecitabine chemotherapy will be administered in Cycle 2 and Cycles ≥ 4 of the Treatment Period to patients who progressed on nanoliposomal irinotecan fluorouracil/leucovorin during the Bridging Therapy Period. Treatment will continue until the development of disease progression.
Biological: Anti-CEA CAR-T cells
Doses will be delivered by hepatic arterial infusions using a pressure enabled drug delivery (PEDD) device
Other Names:
  • SureFire Precision Infusion System
  • K171355
  • TriSalus PEDD

Drug: Capecitabine
systemic chemotherapy regimen
Other Name: Xeloda

Active Comparator: 3rd Line: NLIR+FU/FA Alone
Patients randomized to the chemotherapy alone treatment arm who developed disease progression during the Bridging Therapy Period while receiving nab paclitaxel plus gemcitabine will be treated with nanoliposomal irinotecan plus fluorouracil/leucovorin during the Treatment Period.
Drug: NLIR+FU/FA
systemic chemotherapy regimen
Other Names:
  • Onivyde
  • Adrucil
  • Leucovorin

Active Comparator: 3rd Line: Capecitabine Alone
Patients that developed disease progression during the Bridging Therapy Period while receiving nanoliposomal irinotecan plus 5-FU/leucovorin will be treated with capecitabine during the Treatment Period.
Drug: Capecitabine
systemic chemotherapy regimen
Other Name: Xeloda




Primary Outcome Measures :
  1. Assess efficacy by overall survival [ Time Frame: 6 - 12 months ]
    As a measure of activity, Overall Survival (OS) will be assessed. The events for the assessment of OS are death events. Time to event endpoints will be estimated using Kaplan-Meier methods. Point estimates and 95% confidence intervals will be provided where applicable.


Secondary Outcome Measures :
  1. Assess safety by monitoring adverse events [ Time Frame: 6 - 12 months ]
    As a measure of safety, the types, frequencies, and severities of adverse events and their relationship to study drug will be summarized.

  2. Assess efficacy by within-liver progression free survival (PFS) [ Time Frame: 6 - 12 months ]
    As a measure of activity, within-liver PFS will be assessed. The events for the assessment of within-liver PFS will be measured from the date of randomization to the date of disease progression within the liver or death, whichever comes first. This time to event endpoint will be estimated using Kaplan-Meier methods. Point estimates and 95% confidence intervals will be provided where appropriate.

  3. Assess efficacy by progression free survival (PFS) [ Time Frame: 6 - 12 months ]
    As a measure of activity, PFS will be assessed. The events for the assessment of PFS will be measured from the date of randomization to the date of disease progression or death, whichever comes first. This time to event endpoint will be estimated using Kaplan-Meier methods. Point estimates and 95% confidence intervals will be provided where appropriate.

  4. Assess efficacy by within-liver time to progression (TTP) [ Time Frame: 6 - 12 months ]
    As a measure of activity, within-liver TTP will be assessed. The events for the assessment of within-liver TTP will be measured from the date of randomization to the date of disease progression within the liver. This time to event endpoint will be estimated using Kaplan-Meier methods. Point estimates and 95% confidence intervals will be provided where appropriate.

  5. Assess efficacy by time to progression (TTP) [ Time Frame: 6 - 12 months ]
    As a measure of activity, TTP will be assessed. The events for the assessment of TTP will be measured from the date of randomization to the date of disease progression. This time to event endpoint will be estimated using Kaplan-Meier methods. Point estimates and 95% confidence intervals will be provided where appropriate.

  6. Assess efficacy by within-liver radiographic response rate using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) [ Time Frame: 6 - 12 months ]
    As a measure of activity, overall response rate within-liver will be assessed using radiographic scans using RECIST v 1.1 criteria. Response will be assessed for each patient over a 6- to 12-month timeframe during the Treatment and Observation Periods of the protocol.

  7. Assess efficacy by overall whole-body radiographic response rate using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) [ Time Frame: 6 - 12 months ]
    As a measure of activity, overall response rate for overall whole-body will be assessed using radiographic scans using RECIST v 1.1 criteria. Response will be assessed for each patient over a 6- to 12-month timeframe during the Treatment and Observation Periods of the protocol.

  8. Assess efficacy by duration of response within-liver in accordance with RECIST v 1.1 criteria [ Time Frame: 6 - 12 months ]
    As a measure of activity, duration of response within-liver will be measured using radiologic scans and assessed according to RECIST v1.1 criteria. This will be assessed for each patient over a 6- to 12-month timeframe during the Treatment and Observation Periods of the protocol.

  9. Assess efficacy by duration of response of overall whole-body in accordance with RECIST v 1.1 criteria [ Time Frame: 6 - 12 months ]
    As a measure of activity, duration of response of overall whole-body will be measured using radiologic scans and assessed according to RECIST v1.1 criteria. This will be assessed for each patient over a 6- to 12-month timeframe during the Treatment and Observation Periods of the protocol.

  10. Assess efficacy by serologic response rates by CEA levels [ Time Frame: 6 - 12 months ]
    As a measure of activity, overall response rate will be assessed by serologic CEA levels. Response rate will be assessed for each patient over a 6- to 12-month timeframe during the Treatment and Observation Periods of the protocol.

  11. Assess efficacy by serologic response rates by CA 19-9 levels [ Time Frame: 6 - 12 months ]
    As a measure of activity, overall response rate will be assessed by serologic CA 19-9 levels. Response rate will be assessed for each patient over a 6- to 12-month timeframe during the Treatment and Observation Periods of the protocol.

  12. Evaluation of Quality-of-Life using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) [ Time Frame: 6 - 12 months ]
    As a measure of quality-of-life, the EORTC QLQ-C30 instrument will be administered at months 2, 4, 6 of the Treatment Period and at the end of study.

  13. Evaluation of Quality-of-Life using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Pancreatic Cancer Module (EORTC QLQ-PAN26) [ Time Frame: 6 - 12 months ]
    As a measure of quality-of-life specific for patients with pancreatic cancer, the EORTC QLQ-PAN26 instrument will be administered at months 2, 4, 6 of the Treatment Period and at the end of study.

  14. Evaluation of Quality-of-Life using the 5-level EQ-5D version (EQ-5D-5L) questionnaire [ Time Frame: 6 - 12 months ]
    As a measure of quality-of-life, the EQ-5D-5L questionnaire will be administered at months 2, 4, 6 of the Treatment Period and at the end of study.


Other Outcome Measures:
  1. Assess if serum cytokine levels correlate with response and/or toxicity to hepatic arterial infusions [ Time Frame: 6 - 12 months ]
    As an exploratory analysis, serum cytokine levels (pg/mL) will be measured over time by a standard laboratory test using Enzyme-linked immunosorbent assay (ELISA) to determine if increases in cytokines predict response and/or toxicity to liver arterial infusions.

  2. Assess if neutrophil: lymphocyte ratio (NLR) correlate with response from hepatic arterial infusions [ Time Frame: 6 - 12 months ]
    As an exploratory analysis, NLR will be calculated to determine if there is a correlation with response and/or toxicity.

  3. Assess the persistence of CAR-T cells in liver tumor biopsies over time. [ Time Frame: 6 - 12 months ]
    As an exploratory analysis, the engraftment of CAR-T cells in planned liver tumor biopsies will be analyzed to assess persistence of CAR-T cells during the Treatment and Observation Periods of the study.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have documented CEA-expressing pancreatic adenocarcinoma with unresectable liver metastases. Documentation of CEA-expressing adenocarcinoma may be demonstrated by an elevated serum CEA level (≥ 10 ng/mL) or by the detection of CEA on the cell surface of adenocarcino3.
  • Documentation of disease progression of pancreatic adenocarcinoma following the initiation of first-line treatment with FOLFIRINOX or gemcitabine-based therapy.ma cells by immunohistochemistry (IHC).
  • The primary pancreatic tumor may be intact and limited lung metastases (≤ 3 lesions, none > 1 cm in longest diameter) and lymphoid metastases (≤ 3 lesions, none > 1 cm in longest diameter) are permitted.
  • There must be at least one measurable metastatic liver lesion ( ≥ 10 mm in longest diameter).
  • ECOG performance status of 0 or 1.
  • Be willing and able to comply with the study schedule and all other protocol requirements.
  • Females of childbearing potential must have 2 negative pregnancy tests prior to the start of study treatment, and must agree to pregnancy tests during the study; sexually active female and male patients must be willing to use an effective birth control to avoid pregnancy.

Exclusion Criteria:

  • Received anti-cancer chemotherapy or investigational systemic anti-cancer treatments other than first line FOLFIRINOX or gemcitabine-based chemotherapy for advanced pancreatic adenocarcinoma.
  • Received FOLFIRINOX or gemcitabine-based therapy within 14 days before receiving the first dose of study treatment.
  • Have any unresolved toxicity > Grade 1 from previous anticancer therapy, except for stable chronic toxicities (≤ Grade 2) that are not expected to resolve.
  • Have a history of histologically confirmed metastases outside the liver, lungs, or lymph nodes.
  • More than 50% replacement of one or both hepatic lobes with tumor.
  • Tumor causing biliary obstruction not amenable to stenting.
  • Received prior anti-CEA agents, CAR-T, CAR-T cell line, CAR-NK, CAR-pNK, or CAR-NK cell line therapies.
  • Have any clinically significant low baseline lab results for hemoglobin, platelet counts, or neutrophil counts at screening.
  • Has any untreated or ongoing intra-abdominal infection or bowel obstruction.
  • Has any clinically significant elevated baseline lab results for serum creatinine, aspartate aminotransferase (AST), and total bilirubin (except for patients in whom hyperbilirubinemia is attributed to Gilbert's syndrome), and alkaline phosphatase at screening.
  • Known HIV or acquired immunodeficiency syndrome-related illness, acute or history of chronic hepatitis B or C.
  • Female patients who are pregnant or breastfeeding.
  • Has active bacterial, viral or fungal infections.
  • Has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from participating in the study.
  • Has any condition, including the presence of laboratory abnormalities that places the patient at an unacceptable risk if the patient was to participate in the study.
  • Are receiving medications that are strong inducers CYP3A4 or CYP2C8 within 2 weeks of initiating treatment in the Bridging Therapy Period (rifampicin, carbamazepine, phenytoin, efavirenz, nevirapine, rifabutin, rifapentine, St. John's wort).
  • Are receiving medications that inhibit CYP3A4 or CYP2C8 within 1 week of initiating treatment in the Bridging Therapy Period (ketoconazole and other imidazole antifungals, erythromycin, clarithromycin, itraconazole, voriconazole, fluoxetine, gemfibrozil, cimetidine, lopinavir, nefazodone, telaprevir, ritonavir, saquinavir, indinavir, or nelfinavir).
  • Are receiving medications that inhibit UGT1A1 within 1 week of initiating nanoliposomal irinotecan therapy (atazanavir, gemfibrozil, indinavir).
  • Left ventricular ejection fraction (LVEF) < 40%

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04037241


Contacts
Layout table for location contacts
Contact: Ying Yan, MD MS 858-203-4100 ext 4183 yyan@sorrentotherapeutics.com
Contact: Mike Royal, MD JD MBA 858-203-4100 ext 4146 mroyal@sorrentotherapeutics.com

Sponsors and Collaborators
Sorrento Therapeutics, Inc.
Investigators
Layout table for investigator information
Study Director: Ying Yan, MD MS Sorrento Therapeutics
Layout table for additonal information
Responsible Party: Sorrento Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT04037241    
Other Study ID Numbers: STI-CEA-201
First Posted: July 30, 2019    Key Record Dates
Last Update Posted: July 15, 2020
Last Verified: July 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Leucovorin
Gemcitabine
Paclitaxel
Capecitabine
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antimetabolites
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antidotes
Protective Agents
Vitamin B Complex
Vitamins